IO Biotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, IO Biotech's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 88.1 M in 2026, whereas Net Debt is likely to drop (54.9 M) in 2026. Key indicators impacting IO Biotech's financial strength include:
The financial analysis of IO Biotech is a critical element in measuring its lifeblood. Investors should not minimize IO Biotech's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Understanding current and past IO Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of IO Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in IO Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in IO Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IO Biotech. Check IO Biotech's Beneish M Score to see the likelihood of IO Biotech's management manipulating its earnings.
IO Biotech Stock Summary
IO Biotech competes with Werewolf Therapeutics, Spruce Biosciences, Adicet Bio, OUTLOOK THERAPEUTICS, and Cue Biopharma. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what IO Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining IO Biotech's current stock value. Our valuation model uses many indicators to compare IO Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IO Biotech competition to find correlations between indicators driving IO Biotech's intrinsic value. More Info.
IO Biotech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, IO Biotech's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value IO Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
IO Biotech Systematic Risk
IO Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. IO Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on IO Biotech correlated with the market. If Beta is less than 0 IO Biotech generally moves in the opposite direction as compared to the market. If IO Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one IO Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of IO Biotech is generally in the same direction as the market. If Beta > 1 IO Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in IO Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various IO Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of IO Biotech growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of IO Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of IO Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of IO Biotech based on widely used predictive technical indicators. In general, we focus on analyzing IOBT Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build IO Biotech's daily price indicators and compare them against related drivers.
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.